Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 14/20 | 0.39 |
| ▸ | BRD2 | P25440 | 11/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 11/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 6/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15975168 | 0.84 | BRD4 (0.40) | MEN1RAB9AKMT2AGAAKDM4E | |
| SCHEMBL15148291 | 0.79 | BRD4 (0.50) | MEN1RAB9AKMT2AGAAKDM4E | |
| SCHEMBL14993903 | 0.77 | BRD4 (0.38) | GAAKDM4EALDH1A1BRD4BRD2 | |
| SCHEMBL1856897 | 0.77 | HDAC8 (0.35) | GAAKDM4EALDH1A1BRD4BRD2 | |
| SCHEMBL2114179 | 0.77 | KDM4E (0.38) | GAAKDM4EALDH1A1BRD4BRD2 | |
| SCHEMBL7257366 | 0.77 | MEN1 (0.45) | MEN1RAB9AKMT2AGAAKDM4E | |
| SCHEMBL27295583 | 0.77 | ACLY (0.43) | MEN1RAB9AKMT2AGAAKDM4E | |
| SCHEMBL19513805 | 0.77 | MEN1 (0.41) | MEN1RAB9AKMT2AGAAKDM4E | |
| SCHEMBL14993737 | 0.77 | AURKA (0.49) | MEN1RAB9AKMT2AGAAKDM4E | |
| SCHEMBL24923650 | 0.74 | BRD4 (0.35) | MEN1RAB9AKMT2AGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1304325-A1 | 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-23 | — | — | EP | claimed |
| US-8158652-B2 | 1-Difluoromethyl-5-{4-[3-(1-piperidinyl)propoxy]phenyl}-2(1H)-pyridone; compounds act as histamine-H3 receptor antagonistic substances or inverse-agonistic substances; useful as preventives or remedies for various circular system diseases, nervous system diseases, metabolic system diseases | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20080269287-A1 | Substituted Pyridone Derivative | MSD K.K. (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1820797-A1 | SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
| EP-1304325-A1 | 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-23 | — | — | EP | disclosed |
| WO-2001055113-A1 | PROCESSES FOR DECHLORINATING PYRIDINES | REILLY INDUSTRIES, INC. (US) | 2001-08-02 | — | — | WO | disclosed |
| US-6051714-A | DECHLORINATION OF CHLORINATED PYRIDINES WITH ZINC IN THE PRESENCE OF PHASE TRANSFER CATALYSTS AND ALKALINE REAGENTS | REILLY INDUSTRIES, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0026736-B1 | PROCESS FOR PREPARING 2,3,5-TRICHLOROPYRIDINE AND AMMONIUM SALTS OF THE METHYL ESTER OF METHANE PHOSPHONIC ACID, AND THEIR PREPARATION | CIBA-GEIGY AG (CH) | 1984-12-05 | — | — | EP | disclosed |
| EP-0040176-B1 | PROCESS FOR THE PREPARATION OF 2,3,5-TRICHLOROPYRIDINE | CIBA-GEIGY AG (CH) | 1984-02-15 | — | — | EP | disclosed |
| US-4379938-A | Process for producing 2,3,5-trichloropyridine | CIBA-GEIGY CORPORATION (US) | 1983-04-12 | — | — | US | disclosed |
| EP-0040176-A1 | Process for the preparation of 2,3,5-trichloropyridine | CIBA-GEIGY AG (CH) | 1981-11-18 | — | — | EP | disclosed |
| US-4287347-A | Process for producing 2,3,5-trichloropyridine | CIBA-GEIGY CORPORATION (US) | 1981-09-01 | — | — | US | disclosed |
| EP-0026736-A2 | Process for preparing 2,3,5-trichloropyridine and ammonium salts of the methyl ester of methane phosphonic acid, and their preparation | CIBA-GEIGY AG (CH) | 1981-04-08 | — | — | EP | disclosed |
| US-4258194-A | Process for producing 2,3,5-trichloropyridine | CIBA-GEIGY CORPORATION (US) | 1981-03-24 | — | — | US | disclosed |
| US-4245098-A | BY REACTING TRICHLOROACETALDEHYDE WITH ACRYLONITRILE | CIBA-GEIGY CORPORATION (US) | 1981-01-13 | — | — | US | disclosed |
| EP-0012117-A1 | Process for the preparation of 2,3,5-trichloropyridine; 2,4,4-trichloro-4-formyl-butyronitrile and process for its preparation | CIBA-GEIGY AG (CH) | 1980-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269287-A1 | Substituted Pyridone Derivative | HRH3, HRH4, HRH1 | MEN1 1263/4885RAB9A 3851/4885KMT2A 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.